10x Genomics (TXG) Share-based Compensation (2018 - 2026)

10x Genomics has disclosed Share-based Compensation across 9 years of filings, most recently posting $22.6 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $22.6 million, down 27.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $100.7 million (down 25.8% YoY), and the FY2025 annual result was $109.1 million, down 22.47% from the prior year.
• Share-based Compensation came in at $22.6 million for Q1 2026 at 10x Genomics, down from $25.2 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $45.7 million in Q2 2023 to a low of $22.6 million in Q1 2026.
• The 5-year median for Share-based Compensation is $33.6 million (2024), against an average of $33.9 million.
• Across the five-year window, Share-based Compensation surged 61.63% in 2023 and decreased 28.4% in 2025, its largest moves.
• 10x Genomics' Share-based Compensation stood at $41.0 million in 2022, then declined by 5.02% to $38.9 million in 2023, then declined by 16.39% to $32.5 million in 2024, then slipped by 22.5% to $25.2 million in 2025, then declined by 10.22% to $22.6 million in 2026.
• The last three Share-based Compensation figures came in at $22.6 million (Q1 2026), $25.2 million (Q4 2025), and $25.3 million (Q3 2025), per Business Quant data.